Compare LyondellBasell Industries NV (LYB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Organon & Co. Common Stock — how do they compare? LyondellBasell Industries NV trades at $61.17 (market cap $19.39B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: LyondellBasell Industries NV is far larger — about 5.4× Organon & Co. Common Stock's market cap, and LyondellBasell Industries NV pays the higher dividend (4.6%). Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 88 Days and Organon & Co. Common Stock for 0 Days on average.
| LYB | OGN | |
|---|---|---|
Market Cap | $19.39B | $3.62B |
Volume | 3,160,509 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $13.81 |
52-Week Low | $42.28 | $5.70 |
Typical Hold Time | 88 Days | 0 Days |
Enterprise Value | $30.98B | $11.04B |
Dividend Yield | 4.6% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $61.17, up 2.96% today, with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $745 million in 2025, with revenue declining to $30.15 billion, though recent quarters have beaten EPS estimates. Analyst sentiment is balanced with a 45% buy and 45% hold rating, and a consensus price target of $68.56 suggests modest upside. The dividend yield remains a key focus amid sector challenges.
The outlook for LYB hinges on earnings recovery and dividend sustainability. Opportunities include operational leverage and favorable market conditions, but risks involve persistent negative margins, high debt levels, and competitive pressures. The stock's performance will likely depend on reversing profitability trends and maintaining investor confidence through consistent dividend payments.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
